German medical device company B. Braun Melsungen has dropped its appeal of a ruling invalidating three of its intravenous catheter patents and finding rival Becton Dickinson did not infringe the patents.
The consumer regulator has dragged Western Australia’s Quantum Housing and its sole director to court for allegedly engaging in unconscionable conduct and false, misleading or deceptive conduct in relation to a government-sponsored affordable housing program that incentivises below-market rentals.
International law firm King & Wood Mallesons has nabbed two leading litigators to bolster the ranks of its dispute resolution practice, the firm said Friday.
Nine Network has been ordered to pay a British tourist $100,000 in a defamation suit over a news broadcast that aired following his acquittal on assault charges related to a brawl with rugby player that used the term “coward punch” to describe the dust-up.
The Australian Securities and Investments Commission has won its bid for a court order placing Melbourne-based forex trader Berndale Capital into receivership for allegedly failing to safeguard client money.
Qantas has failed in its bid to appeal a decision by the Fair Work Commission to allow a terminated employee’s late unfair dismissal application to proceed because the worker’s solicitor was to blame for the delay.
Two units of private equity company Antin Infrastructure Partners have taken their legal battle with Spain to Australian court, filing a lawsuit to enforce a $161 million arbitration award related to investments the companies made in two solar plants in southern Spain.
Building products supplier Wagners has taken its largest cement customer, Boral, to court in a dispute over pricing, and will take a $10 million hit to its 2019 earnings as a result.
After losing its fight for a temporary injunction, Sanofi-Aventis has dropped its patent lawsuit against Alphapharm over the generic drug maker’s plans to market a competing insulin injector pen in Australia.
A judge has refused an application by generic drug maker Juno Pharmacueticals to withdraw an admission in a battle with Millennium Pharmaceuticals over its cheap version of breakthrough cancer drug Velcade, denying Juno a potential defence to allegations of patent infringement.